Alessandra Tedeschi, EHA 2019 – Ibrutinib for First-line Treatment of CLL
We are joined by Alessandra Tedeschi at EHA 2019 to discuss her presentation on the five-year follow-up of patients receiving ibrutinib for first-line treatment of chronic lymphocytic leukemia (CLL).
Questions
1. How does ibrutinib fit into the treatment paradigm for chronic lymphocytic leukemia? (0:05)
2. What were the major findings of the long-term follow-up of the RESONATE-2 study? (0:27)
3. Which patient subgroups were most likely to experience durable responses? (1:09)
4. What is the long-term safety profile of ibrutinib? (1:38)
5. What are the treatment options for patients who discontinue ibrutinib therapy? (2:13)
Alessandra Tedeschi has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
